The inflammatory bowel disease market is rapidly growing, driven by unmet patient needs despite existing therapies. Major pharma acquisitions highlight strong demand for innovative treatments. Abivax’s...
The publication of the results of the phase IIa clinical trial, evaluating ABX464 in hemorrhagic recto colitis, has been driving the stock market price of Montpellier...